Subscribe
tibor-duris-shutterstock-com-pills-
Tibor Duris / Shutterstock.com
5 January 2017Americas

Par Pharmaceutical in pre-emptive strike to protect Latuda generic

Par Pharmaceutical has sought a declaratory judgment that it did not infringe patents belonging to Sumitomo and its subsidiary Sunovion that protect bipolar disorder drug Latuda (lurasidone hydrochloride).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Japanese firm acquires US drugmaker after increasing offer
25 October 2022   The deal sees Sumitomo acquiring ownership of cancer and uterine fibroid treatments | Myovant initially rejected low offer that “undervalued” the company.
Americas
Sumitomo sues over antipsychotic drug
14 February 2018   Japan-based Sumitomo Dainippon Pharma has taken on Indian generics company Emcure Pharmaceuticals over an antipsychotic drug.


Editor's picks

UKIPO rejects Boehringer’s SPC for horse inhaler
Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025

Editor's picks

Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025
Americas
Bankruptcy judge approves $305m sale of genetics testing company
1 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

More on this story

Big Pharma
Japanese firm acquires US drugmaker after increasing offer
25 October 2022   The deal sees Sumitomo acquiring ownership of cancer and uterine fibroid treatments | Myovant initially rejected low offer that “undervalued” the company.
Americas
Sumitomo sues over antipsychotic drug
14 February 2018   Japan-based Sumitomo Dainippon Pharma has taken on Indian generics company Emcure Pharmaceuticals over an antipsychotic drug.

More on this story

Big Pharma
Japanese firm acquires US drugmaker after increasing offer
25 October 2022   The deal sees Sumitomo acquiring ownership of cancer and uterine fibroid treatments | Myovant initially rejected low offer that “undervalued” the company.
Americas
Sumitomo sues over antipsychotic drug
14 February 2018   Japan-based Sumitomo Dainippon Pharma has taken on Indian generics company Emcure Pharmaceuticals over an antipsychotic drug.

More features

WATCH: The transparency tightrope—balancing innovation, regulation, and IP protection in a new era
Chicago firm Much Shelist adds partner with ‘entrepreneurial mindset’
Powell Gilbert launches Düsseldorf office with leading patent litigator
Startups toolkit: Why investors want more than patents
J&J fends off generic schizophrenia drug bids
Kilpatrick adds ‘seasoned litigator’ as trademark partner
WATCH: An update on EPO Board of Appeal strategy for 2025 and beyond
Startup challenges rival over brain monitoring tech at ITC